These data suggest that a combination of DNA‐PKcs with NU7441 and BRAF (downstream of HRasV12) with Dabrafenib – which are in the same pathway as demonstrated in this study‐ could not yield appreciable synergistic effects in NHA/HRasV12/TRIM24‐driven Ep‐GBM‐like tumorigenicity. The gene discussed is BRAF; the disease is glioblastoma.